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Abstract
PURPOSE: Current clinical practice guidelines sometimes still recommend
stopping aspirin five to seven days before knee arthroplasty surgery. Literature
regarding multimodal blood management and continuation of anti-platelet therapy
in this type of surgery is scant. The study hypothesis was that knee arthroplasty
under low-dose aspirin mono-therapy continuation does not cause more total
blood loss than knee arthroplasty performed without aspirin. Blood loss would
be measured by haemoglobin (Hb) and haematocrit (HTC) levels drop at day
2 or day 4 for patients who benefit from multimodal bleeding control measures.
METHODS: A database of all patients undergoing knee arthroplasty between
2006 and 2014 was analysed. Demographic, surgical and complete blood workup
data were collected. A retrospective comparison study analysed both groups in
terms of blood loss, by mean calculated blood loss as haemoglobin or haematocrit
drop between the preoperative Nadir value and the postoperative day 2 ...
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Results There were no differences in terms of visible 
(early) or hidden (late) blood loss as measured by Hb drop 
in between both groups. There is no difference in transfu-
sion rates.
Conclusions Modern multimodal blood management pro-
vides sufficient blood loss prevention during and after knee 
arthroplasty to allow physicians to continue low-dose aspi-
rin mono-therapy for cardiovascular prevention.
Level of evidence III.
Keywords Total knee arthroplasty · Unicompartmental 
knee arthroplasty · Blood loss · Haemoglobin · Aspirin
Introduction
Joint arthroplasty is considered a high-risk procedure 
both for bleeding and for venous thromboembolic events 
(VTE) (4,15). Knee arthroplasty can result in substantial 
bleeding ranging, according to different authors, from 500 
to 1500 ml of estimated blood loss [12, 25, 26]. When hid-
den blood loss is considered and a calculated blood loss 
(CBL) formula, based on haemoglobin changes, is used, 
volumes of 1000–2000 ml can be observed [18, 23, 31, 34]. 
Transfusion rates after TKA can range as high as 63–94 %, 
according to some authors [2, 10, 31].
Aspirin, an irreversible cyclo-oxygenase (COX) enzyme 
inhibitor, is frequently used for treating common health 
problems as well as for cardiovascular prevention at both 
the primary (preventing first occurrence of disease) and 
secondary level (preventing recurrence of disease). Aspirin 
is not only a non-steroidal anti-inflammatory drug but also 
an anti-platelet agent (4, 27). It works by inhibiting the syn-
thesis of thromboxane A2 (TXA2), a potent stimulator of 
platelet aggregation, and therefore inhibits platelet pooling 
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Purpose Current clinical practice guidelines sometimes 
still recommend stopping aspirin five to seven days before 
knee arthroplasty surgery. Literature regarding multimodal 
blood management and continuation of anti-platelet ther-
apy in this type of surgery is scant. The study hypothesis 
was that knee arthroplasty under low-dose aspirin mono-
therapy continuation does not cause more total blood loss 
than knee arthroplasty performed without aspirin. Blood 
loss would be measured by haemoglobin (Hb) and haema-
tocrit (HTC) levels drop at day 2 or day 4 for patients who 
benefit from multimodal bleeding control measures.
Methods A database of all patients undergoing knee 
arthroplasty between 2006 and 2014 was analysed. Demo-
graphic, surgical and complete blood workup data were 
collected. A retrospective comparison study analysed both 
groups in terms of blood loss, by mean calculated blood 
loss as haemoglobin or haematocrit drop between the pre-
operative Nadir value and the postoperative day 2 and 4 
value. A group of 198 (44 UKA and 154 TKA) patients 
underwent surgery without interrupting their aspirin ther-
apy for cardiovascular prevention. Mean (SD) age was 
71 (8) and the mean (SD) BMI was 29 (5.5) kg/m2. The 
control group consisted of 403 (102 UKA and 301 TKA) 
patients who were not under aspirin, or any other anti-
platelet agent. Mean (SD) age was 65 (10) (p < 0.05) and 
the mean (SD) BMI was 29 (5.0) kg/m2 (n.s.). All patients 
in the control group were randomly selected.
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for 8–10 days [15, 29]. Because of its anti-platelet effect, 
aspirin is often used for thromboprophylaxis following car-
diac stent procedures but has also been reported to reduce 
the frequency of venous thrombosis (VTE), pulmonary 
embolism (PE) and occlusive arterial events [5]. In many 
studies on aspirin continuation, a bleeding event (minor or 
major) was documented [23, 26].
The American Academy of Orthopedics Surgeons 
(AAOS) in its 2011 guidelines recommends discontinu-
ing anti-platelet therapy prior to undergoing elective hip 
and knee replacement surgery (moderate recommendation 
grade) [23]. Similarly, recent clinical practice guidelines 
on aspirin use for primary prevention in patients with coro-
nary disease as well as a guideline for primary prevention 
of arterial thromboembolism by the American College of 
Chest Physicians (ACCP) propose stopping aspirin seven to 
10 days before surgery [13, 21]. The side effects of abruptly 
interrupting aspirin therapy can be important. Aspirin with-
drawal causes a more rapid return of platelet aggregation 
and a platelet rebound phenomenon in the setting of acute 
aspirin withdrawal. This rebound period is characterized by 
increased thromboxane production, decreased fibrinolysis, 
an increase in fibrin strength and a resultant clinical pro-
thrombotic state [6, 14]. Preoperative aspirin cessation might 
increase the risk of acute cardiovascular events up to 10.2 
and 6.1 % for lower limb ischaemic events after surgery [8, 
9, 11]. A meta-analysis of 50,279 patients taking low-dose 
aspirin for secondary prevention showed that the risk of arte-
rial thromboembolism after aspirin withdrawal was threefold 
higher than in those who continued taking it [8].
The correct peri-operative management of aspirin is still 
a remaining challenge, finding the balance between the 
bleeding risk and the potential thromboembolic complica-
tions of an aspirin withdrawal syndrome (8). Multimodal 
blood reduction measures are part of the peri-operative 
management in most of the arthroplasty centres around 
the world (18, 23, 31). The hypothesis of this retrospective 
study was that current multimodal blood management is 
sufficiently performing to reduce visible and hidden blood 
loss enough to allow low-dose aspirin mono-therapy con-
tinuation in the peri-operative phase of TKA surgery.
Materials and methods
A prospective database with blood tests performed preop-
eratively at day 2 and day 4 was available for all patients 
undergoing primary knee arthroplasty from 2006 to 2014 
in our department. In this study, patients undergoing mini-
mally invasive (MI) knee arthroplasty for osteoarthritis, by 
a single surgeon (ET), in the Saint Luc University Hospital, 
Brussels, Belgium, were retrospectively reviewed for blood 
loss. The data were retrieved from the operating software 
for patients’ medical records of our institution (Medical 
Explorer v3r9 Saint-Luc Hospital, 2008). One group of 198 
(44 UKA and 154 TKA) patients operated on under low-
dose aspirin continuation was selected from all consecutive 
cases. These patients were under aspirin mono-therapy for 
cardiovascular prevention and had followed the advice not 
to stop their aspirin treatment. The other group consisted of 
a random sample of 403 (102 UKA and 301 TKA) patients 
operated on without having ever been under aspirin. The 
Ethical Committee of the Saint Luc University hospi-
tal, Brussels, Belgium, approved this retrospective study 
(B4032011111567).
The inclusion criterion for the group under aspirin 
was ongoing, peri-operative low-dose aspirin therapy. 
The inclusion criteria for the group without aspirin were 
absence of current or recent aspirin therapy, no history of 
cardiovascular events (myocardial infarction or stroke), 
no bleeding events, no history of deep vein thrombo-
sis (DVT) or pulmonary embolism (PE), a Lee score of 
I (postoperative cardiovascular events risk score), or an 
American Society of Anesthesiologist score (ASA) of 1 
or 2. The exclusion criteria for both groups were previ-
ous high tibial osteotomy or arthrotomy except for open 
meniscectomy, presence of metallic hardware, known 
bleeding disorders, diagnosis other than osteoarthritis, 
and use of anti-aggregation therapy like clopidogrel-con-
taining products or anticoagulation therapy (anti-vitamin 
K or heparin) before surgery. Demographic data and base-
line characteristics of both study groups at baseline are 
given in Table 1.
Multimodal blood management protocol
General anaesthesia was used for all included patients with 
intensive per-operative temperature monitoring and pre-
vention of hypothermia. At induction 1 g of tranexamic 
acid was administered to all patients. Prior to incision, the 
tourniquet was inflated to 280 mmHg and released after 
implantation of all components. An identical minimally 
invasive medial approach was performed in both groups. 
A mean (SD) incision length of 12 (2) cm was made for 
the UKA and a mean (SD) length of 16 (4) cm was made 
for the TKA. All UKA patients received a cemented ZUK 
(Zimmer, Warsaw, USA) with metal backing of the tibial 
component. An extramedullary guide was used on the tibial 
side with a spacer technique for the femoral side. All TKA 
patients received a cemented, posterior stabilized Vanguard 
(Zimmer Biomet, Warsaw, USA) prosthesis with resurfac-
ing of the patella. An extramedullary guide was used on 
the tibial side and the femoral hole was plugged in every 
TKA. Bovie coagulation was used on the soft tissue areas 
and nothing was used on the bony surfaces. No drains were 
used.
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Table 1  Demographic data and 
baseline characteristics of both 
study groups
Variables Total With aspirin Without aspirin P
Number of patients 601 198 403
Mean age (SD) 67 (10) 71 (8) 65 (10) <0.05
Mean BMI (SD) 29 (5) 29 (5.5) 29 (5) n.s.
Gender
Women 390 113 277
Men 211 85 126
Type of prevention aspirin use
Primary 121 121 0
Secondary 77 77 0
Dose of aspirin
80 mg 138 138 0
100 mg 46 46 0
160 mg 12 12 0
330 mg 2 2 0
History of cardiac events
Total 121 106 0
Myocardial infarction 37 37 0
Stroke 10 10 0
Other 74 74 0
History of bleeding events 55 55 0
History of thrombosis events
Total 40 40 0
Deep vein thrombosis 30 30 0
Pulmonary embolism 10 10 0
Diabetic
Type 1 2 2 0
Type 2 46 46 0
Renal failure 15 15 0
Tobacco use
Current 19 19 0
History 35 35 0
Antihypertensive treatment 163 163 0
Knee arthroplasty
UKA 146 44 102
TKA 455 154 301
Lee score
I 530 127 403
II 59 59 0
III 10 10 0
IV 2 2 0
ASA score
1 50 2 48
2 515 160 355
3 36 36 0
Postoperative anti-thrombosis prevention
Enoxaparin 49 7 42
Nadroparin 522 180 342
Rivaroxaban 30 11 19
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The rehabilitation program was identical for both 
groups with full weight bearing without aids and active 
range of motion exercises from day 1. Thrombosis proph-
ylaxis consisted of low molecular weight heparin for 
21 days after surgery with enoxaparin (N = 49), nadropa-
rin (N = 522) or rivaroxaban (N = 30). Dose was adapted 
according to the weight of the patient. Criteria for dis-
charge were a dry wound, oral pain medication, no need 
for blood transfusion, ambulation without aid and at least 
90° of active flexion.
Primary outcomes
Hb and HTC levels were determined for each patient before 
and after surgery and on postoperative days 2 and 4 through 
blood tests for both groups. Transfusions, if any, and num-
ber of units transfused, were noted in the prospective data-
base. The American Association of Blood Banks clini-
cal practice guideline on transfusion recommends the use 
of restrictive protocols in which transfusion is considered 
only in patients whose haemoglobin level is ≤8 g/dL. The 
guideline recommends the use of clinical symptoms as well 
as haemoglobin levels in determining when to use transfu-
sion [3, 7, 10, 20]. These criteria were strictly applied and 
the decision to transfuse was taken by our internist (JCY). 
HTC levels and drop in HTC levels were also compared 
between both groups. Total blood loss (TBL), including 
‘visible’ and ‘hidden’ blood loss, was estimated as calcu-
lated blood loss (CBL) using the change in HTC, according 
to Gross et al. [18] with the following formula:
CBL = Total Blood Volume (TBV)
× (HTC initial− HTC final)/HTC mean
The patient’s total blood volume (TBV) was calculated as:
 for men and 
 for women [31].
Secondary outcomes
Tourniquet and total surgical time recorded by the anaes-
thetist were collected for analysis. Hospital stay (LOS) was 
considered in order to evaluate the impact of blood transfu-
sion on LOS, if any.
Statistical analysis
Sample characteristics are presented as numbers, means, 
standard deviations and ranges. The normal distribution 
of the data was assessed by the Kolmogorov–Smirnov 
test. Abnormally distributed data were analysed using 
nonparametric statistical tests for continuous data, such 
as the Mann–Whitney U test for independent samples 
and Student’s t test for dependent samples. Compari-
son of observed proportions was performed using Chi-
square and Fisher’s exact test for categorical data. Sta-
tistical analysis was conducted with SPSS 21 Statistical 
Software (SPSS Inc, Chicago, IL, USA) and signifi-
cance was set at P < 0.05. Based on previous publica-
tions on blood loss, sample size was considered suffi-
cient [30].
TBV = 0.3669 × height (in m3)
+ 0.03219 × weight (in kg) + 0.6041
TBV = 0.3561 × height (in m3)
+ 0.03308 × weight (in kg) + 0.1833
Table 2  Haemoglobin levels in 
the two study groups
Hb (g/dl) (SD) UKA P TKA P
With aspirin Without aspirin With aspirin Without aspirin
Preop 13.7 (1.4) 13.9 (1.3) n.s. 13.4 (1.7) 13.6 (1.3) n.s.
Day 2 13.0 (1.1) 13.0 (1.2) n.s. 11.6 (1.4) 11.8 (1.3) n.s.
Day 4 12.6 (1.4) 12.9 (1.3) n.s. 11.2 (1.4) 11.3 (1.4) n.s.
Day 21 13.1 (1.4) 13.3 (1.2) n.s. 12.1 (1.5) 12.4 (1.2) <0.05
Day 42 13.3 (1.3) 13. (1.1) n.s. 12.8 (1.6) 12.9 (1.2) n.s.
Difference Preop and Day 2 0.9 (0.8) 0.9 (0.9) n.s. 1.8 (1.1) 1.9 (1.1) n.s.
Difference Day 2 and Day 4 0.3 (0.8) 0.1 (0.9) n.s. 0.4 (0.7) 0.4 (0.7) n.s.
Table 3  Calculated blood loss 
in the two study groups
UKA P TKA P
With aspirin Without aspirin With aspirin Without aspirin
CBL (cc) (SD) 369 (213) 508 (289) n.s. 858 (479) 866 (455) n.s.




For UKA patients, both groups had the same preoperative 
haemoglobin level and no differences were observed post-
operatively at days 2, 4, 21 and 42.
For TKA patients, both groups had the same preoperative 
haemoglobin level without significant difference. In addition, 
there were no differences between patients with and with-
out aspirin for visible (between preoperative and day 2) and 
hidden blood loss (between day 2 and day 4). Nevertheless, 
there was a difference in the mean (SD) haemoglobin level 
between the groups at day 21: 12.1 (1.5) g/dL in patients 
with aspirin and 12.4 (1.2) g/dL in patients without aspirin 
(P < 0.05). At day 42, there were no differences between 
both groups. The results are presented in Table 2.
For UKA and TKA, there were no differences in terms 
of calculated blood loss (total blood loss: visible and hid-
den blood loss) between patients with and without aspirin. 
The results are presented in Table 3.
Transfusions occurred only in patients who underwent total 
knee arthroplasty, both with and without aspirin. Three patients 
in each group (a total of six patients) with a preoperative hae-
moglobin level below 11 g/dL required transfusion. There were 
no differences in terms of transfusion between the two TKA 
groups (n.s.). No patients with a preoperative level above 11 g/
dL were transfused. The results are presented in Table 4.
There were no differences in visible and hidden blood 
loss between TKA under aspirin for primary or secondary 
prevention as described by the American College of Chest 
Physicians [13]. The results are presented in Table 5.
Secondary outcomes
There were no differences in terms of surgical time and 
length of hospital stay between the aspirin and control 
group for both UKA and TKA. Nevertheless, there was a 
significant difference between the two TKA groups regard-
ing the tourniquet time: 59 min for patients under aspirin 
and 65 min for patients without aspirin (P < 0.05). For the 
UKA group, there were no differences between both groups 
for tourniquet time. The results are presented in Table 6.
Discussion
The most important finding of this retrospective study was 
that with current multimodal blood management low-dose 
aspirin mono-therapy could be continued in the peri-oper-
ative period of knee arthroplasty. There is no difference 
between patients with and without aspirin in terms of vis-
ible and hidden blood loss, either for unicompartmental or 
for total knee arthroplasty.
Knee arthroplasty is an interesting study model to ana-
lyse the risks or benefits of continuing low-dose aspirin in 
the peri-operative setting. TKA is a surgical procedure that 
is considered at risk both for bleeding and for thromboem-
bolic events [13]. Current literature is still suggesting that 
the bleeding risk is higher than the risk of peri-operative 
thrombotic events, including myocardial infarction and 
stroke. Therefore, the current consensus is still to stop aspi-
rin 5–7 days before knee arthroplasty [13, 23].
Table 4  Transfusion rates in 
the two groups
UKA P TKA P
With aspirin Without aspirin With aspirin Without aspirin
Total number of patients 44 102 154 301
Number of patients transfused 0 0 n.s. 3 3 n.s.
Number of units transfused 0 0 n.s. 4 3 n.s.
Patient with preoperative haemoglobin between 13 and 11 g/dL
 Number 7 19 42 77
 Number transfused 0 0 n.s. 0 0 n.s.
Patient with preoperative haemoglobin <11 g/dL
 Number 2 1 8 5
 Number transfused 0 0 n.s. 3 3 n.s.
Table 5  Haemoglobin levels between patients who take aspirin for 
primary or secondary prevention in TKA
Hb (g/dl) (SD) Primary prevention Secondary prevention P
Preop 13.3 (1.6) 13.5 (1.7) n.s.
Day 2 11.6 (1.4) 11.7 (1.5) n.s.
Day 4 11.2 (1.5) 11.1 (1.4) n.s.
Day 21 12.0 (1.4) 12.2 (1.7) n.s.
Day 42 12.7 (1.6) 13.1 (1.5) n.s.
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Preoperative haemoglobin level is known to be a risk 
factor for transfusion after knee arthroplasty [2, 33]. 
Patients with preoperative haemoglobin levels lower than 
13 g/dL [29] or lower than 11 g/dL [17] are more likely 
to have blood transfusions after knee arthroplasty. In this 
study, no patients with a haemoglobin level between 13 
and 11 g/dL received transfusion. For UKA, none of the 
patients were transfused. As shown in a previous study, 
UKA is a safe procedure in terms of blood loss and risk 
of transfusion [30]. Nevertheless, for TKA there were three 
patients in each group, with a preoperative haemoglobin 
level lower than 11 g/dL, who received transfusion after 
surgery. Knee arthroplasty under aspirin continuation is a 
safe procedure for patients with preoperative haemoglobin 
higher than 11 g/dL; moreover, it does not lead to a greater 
risk of transfusion in patients with a preoperative haemo-
globin level lower than 11 g/dL.
The recent guideline for the use of aspirin in non-
cardiac surgery by the ACCP proposes peri-operative 
antithrombotic management based on risk assessment for 
thromboembolism and bleeding [13]. It is recommended 
that patients be stratified according to their risk of throm-
boembolism. For high-risk patients, such as those taking 
aspirin for secondary prevention, it is recommended that it 
should be continued peri-operatively. For low-risk patients, 
such as those taking aspirin for primary prevention of arte-
rial thromboembolism, stopping aspirin seven to 10 days 
before surgery is still recommended [13]. Our study dem-
onstrated that for both groups, under aspirin for either pri-
mary or secondary prevention purposes, there were no dif-
ferences in terms of blood loss at days 2 and 4. This study 
suggests that we can continue aspirin for high- and low-risk 
patients to minimize the risk of arterial thromboembolism 
in both groups. Continuing aspirin eliminates the need for 
accurate patient stratification and the risk of complications 
in a group that was estimated low risk.
This study has a number of limitations. The first and 
main limitation is that it is a retrospective study. These 
results must be confirmed by a prospective randomized 
study with a higher level of evidence. Nevertheless, this 
study shows that little blood loss is observed during mod-
ern knee arthroplasty under aspirin. All consecutive aspi-
rin patients were included since the day it was decided 
to advice patients (1 January 2011) not to stop aspirin 
anymore before surgery. Furthermore, our large database 
allowed us to randomly select an important control group 
with patients without history of bleeding events, cardiovas-
cular or thrombotic events and tobacco use. The patients 
in this control group all had a co-morbidity score ASA 1 
or 2, as well as a postoperative cardiovascular risk score 
(LEE) of I. The findings of this study are therefore more 
interesting because the control group carried a minimal 
bleeding risk compared to the aspirin continuation group. 
Patients were older and with more co-morbidity since frag-
ile patients are more often under aspirin than the healthy 
ones [2].
A second limitation is the difference in age of each 
study group. The mean age of the group under aspirin was 
71 and the mean age of the group without aspirin was 65 
(P < 0.05). The patients without aspirin that were ran-
domly selected were younger. Ahmed et al. [2] found with 
a regression analysis that patient age is a significant inde-
pendent factor predicting the need for blood transfusion. In 
this study, patients under aspirin had a higher risk of bleed-
ing than the group without aspirin simply because of their 
age. Despite this great discrepancy in terms of risk, no dif-
ferences in blood loss or transfusion were found. The limi-
tation therefore becomes a strength for the study.
A third limitation is that the surgeon (ET) who per-
formed the surgeries is a high-volume arthroplasty surgeon 
interested in blood reduction techniques for many years. 
The experience and training of the surgeon can enter in the 
equation of blood management and offer a protective fac-
tor against bleeding during knee surgery (15, 21, 26, 34). 
Zhang et al. [36] found in their study about the learning 
curve of minimally invasive Oxford phase 3 unicompart-
mental knee arthroplasty that a surgeon with a higher expe-
rience in the field of arthroplasty had a significantly lower 
perioperative blood loss. Aglietti et al. also showed that the 
ideal surgeon for minimally invasive TKA is a trained sur-
geon who is able to anticipate possible sources of mistakes 
and therefore causes less blood loss [1].
A last limitation was that all patients were under 
a deep venous thrombosis (DVT) prevention proto-
col other than aspirin. Therefore, this study did not 
analyse venous thromboembolic events (VTE) as an 
endpoint. Despite this low molecular weight heparin 
regime, no difference in blood loss was observed for the 
Table 6  Secondary outcomes in the two study groups
UKA P TKA P
With aspirin Without aspirin With aspirin Without aspirin
Procedure time min (SD) 73 (10) 77 (19) n.s. 100 (19) 103 (22) n.s.
Tourniquet time min (SD) 46 (15) 49 (15) n.s. 59 (23) 65 (19) <0.05
Length of hospital stay days (SD) 3 (1) 3 (1) n.s. 4 (2) 4 (1) n.s.
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group under low-dose aspirin as compared to the con-
trol group. There were no effusions or prolonged wound 
drainage limiting patients to leave the hospital or ask-
ing for a revision surgery. This observation emphasizes 
that aspirin can be continued in the peri-operative phase 
after knee arthroplasty, even when combined with more 
advanced VTE prophylaxis.
The strength of this study lies in the fact that this is, to 
the best of our knowledge, the first study that shows the 
impact of modern multimodal blood management in knee 
arthroplasty under aspirin mono-therapy continuation with 
a large sample size of 601 knee arthroplasties covering a 
broad population, ranging from ASA 1 to 3. Furthermore, 
the study was performed in standardized conditions with 
all patients operated on by a single surgeon, with the same 
implants for UKA and TKA and under the same type of 
anaesthesia. Blood values were prospectively obtained at 
48 h which seems to be the best timing for Hb level check 
because of ongoing fluid shifts after surgery [34] and also 
at 96 h to evaluate if there is still some late hidden blood 
loss in TKA.
The clinical relevance of this study lies in the fact that 
under multimodal blood management conditions aspirin 
mono-therapy can be continued since bleeding will not 
be more important and therefore the risk for postoperative 
morbidity and mortality of any type of thromboembolic 
event due to aspirin withdrawal syndrome can be avoided.
Conclusions
The decision to stop aspirin mono-therapy, given for pri-
mary prevention, before knee arthroplasty for blood loss 
reduction reasons might not be justified anymore with the 
current multimodal blood management protocols at our 
disposal. Continuing aspirin during unicompartmental and 
total knee arthroplasty appears to be safe for the bleeding 
risk and protects patients from a potential withdrawal syn-
drome, which might cause postoperative cardiovascular, 
arterial and venous thrombotic events.
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